Price$20.46-0.38 (-1.82%)
01:30 PM07:45 PM
News · 26 weeks61+220%
2025-12-142026-06-07
Mix2690d
- Insider11(42%)
- SEC Filings6(23%)
- Other6(23%)
- Analyst1(4%)
- Earnings1(4%)
- M&A1(4%)
Latest news
25 items- PRArtivion to Participate in the 2026 Truist Securities MedTech ConferenceATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m. ET on Tuesday, June 16, 2026. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.About Artivion, Inc.Headquartered in suburban Atlanta, Georgia, A
- INSIDERNew insider Green Andrew M claimed ownership of 60,259 shares (SEC Form 3)3 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Semedo Anthony B. disposed of 6,325 shares and acquired 6,325 shares, decreasing direct ownership by 13% to 40,635 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- SECSEC Form SD filed by Artivion Inc.SD - ARTIVION, INC. (0000784199) (Filer)
- INSIDERAmendment: Director Borgstrom Marna P was granted 7,576 shares, increasing direct ownership by 15% to 56,664 units (SEC Form 4)4/A - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Semedo Anthony B. was granted 7,576 shares, increasing direct ownership by 19% to 46,960 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Salveson Jon W was granted 7,576 shares, increasing direct ownership by 6% to 137,416 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Hoff Elizabeth A was granted 7,576 shares, increasing direct ownership by 28% to 34,765 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Burbank Jeffrey H was granted 7,576 shares, increasing direct ownership by 14% to 61,372 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Bullock James was granted 7,576 shares, increasing direct ownership by 11% to 76,223 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Bevevino Daniel J was granted 7,576 shares, increasing direct ownership by 5% to 157,637 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Ackerman Thomas F was granted 7,576 shares, increasing direct ownership by 5% to 157,472 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Borgstrom Marna P was granted 7,850 shares, increasing direct ownership by 16% to 56,938 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- SECArtivion Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARTIVION, INC. (0000784199) (Filer)
- PREndospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch SystemEndospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE:AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the n
- PRArtivion Completes Acquisition of Endospan Ltd.ATLANTA, May 18, 2026 Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System. Artivion utilized its previously drawn $150 million delayed draw term loan to fund the $135 million upfront net purchase price for Endospan. The transaction also includes potential additional consideration contingent on commercial performance.
- SECArtivion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ARTIVION, INC. (0000784199) (Filer)
- SECSEC Form 10-Q filed by Artivion Inc.10-Q - ARTIVION, INC. (0000784199) (Filer)
- SECArtivion Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARTIVION, INC. (0000784199) (Filer)
- PRArtivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire EndospanFirst Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted share, and non-GAAP net income was $4.2 million, or $0.08 per fully diluted shareAdjusted EBITDA increased 26% to $22.1 million in the first quarter of 2026 compared to $17.5 million in the first quarter of 2025Announced U.S. FDA PMA Approval of the NEXUS Aortic Arch System for the treatment of aortic arch disease, including chronic aortic dissectionsExercised option to a
- PRArtivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial ResultsATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results will be released on Thursday, May 7, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few minutes p
- ANALYSTArtivion upgraded by Ladenburg Thalmann with a new price targetLadenburg Thalmann upgraded Artivion from Neutral to Buy and set a new price target of $42.00
- PRArtivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch SystemEndospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissectionsATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS® Aortic Arch System, developed by Endospan Ltd. ("Endospan"), Artivion's long-standing partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval. Artivion has a $150 million delayed draw term
- SECSEC Form DEFA14A filed by Artivion Inc.DEFA14A - ARTIVION, INC. (0000784199) (Filer)
- SECSEC Form DEF 14A filed by Artivion Inc.DEF 14A - ARTIVION, INC. (0000784199) (Filer)
AORT FAQ
6 questionsWhat does Artivion Inc. do?
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G...Where does AORT stock trade?
Artivion Inc. (AORT) is listed on NYSE.What sector and industry is AORT in?
Artivion Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AORT?
Artivion Inc. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $4200.00 price target on 2026-04-10. Recent price targets range from $2800.00 to $4200.00.What companies are similar to AORT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AORT side-by-side with any of them on Quantisnow.How can I track AORT on Quantisnow?
Quantisnow aggregates Artivion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AORT to receive live email and push alerts on every new disclosure.